Eli Lilly signs manufacturing deal for rheumatoid arthritis drug in Africa, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Eli Lilly signs manufacturing deal for rheumatoid arthritis ***** in *******, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

London: Eli Lilly will license the manufacturing know-how for its rheumatoid arthritis treatment to Egypt’s Eva Pharma, the companies said on Wednesday, to help localise the *****’s production in *******.

Under the agreement, EVA would supply the *****, Olumiant, in 49 countries across *******.

Lilly and EVA have been collaborating since 2021. The companies partnered to manufacture insulin in ******* in 2022.

EVA is set to begin sales of locally manufactured Olumiant by 2026 to the ******** countries.

Olumiant is used for treating rheumatoid arthritis and hair loss caused by an autoimmune ******** called alopecia areata. It recorded $922.6 million in sales last year. (Reporting by Puyaan Singh; Editing by Shilpi Majumdar)

• Published On Sep 4, 2024 at 10:47 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Eli #Lilly #signs #manufacturing #deal #rheumatoid #arthritis #***** #******* #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up